- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01613950
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2
The study is intended to investigate the safety of BYL719 and AUY922 in patients with advanced gastric cancer, and to determine the MTD and/or RDE of both drugs in combination. In addition, the preliminary efficacy of BYL719 in combination with AUY922, and the pharmacokinetics of both drugs will be assessed. Patients will be eligible for this study, if their tumors carry either a molecular alteration of PIK3CA, or an amplification of HER2.
The study includes a dose escalation part followed by a safety expansion phase.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Köln, Germany, 50924
- Novartis Investigative Site
-
Würzburg, Germany, 97080
- Novartis Investigative Site
-
-
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan
- Novartis Investigative Site
-
-
-
-
-
Seoul, Korea, Republic of, 738-736
- Novartis Investigative Site
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 110 744
- Novartis Investigative Site
-
-
-
-
-
Bellinzona, Switzerland, 6500
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10048
- Novartis Investigative Site
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Mass General 2
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction;
- Patients must not have a complete gastrectomy;
- gastric tumors carrying PIK3CA mutation or amplification, or HER2-overexpression, or both;
- at least one but no more than three previous lines of treatment for advanced or metastatic disease;
- Patients with PIK3CA mutated or amplified tumors must have failed at least one line but no more than three lines of standard chemotherapy and/or targeted agents;Patients with HER2 amplified tumor must have failed at least one line, but no more than three lines, with or without anti-HER2 therapy. All HER2 positive patients are expected to have received trastuzumab unless contraindications were present or trastuzumab was unavailable;
- Performance Status (PS) ≤ 1 ;
- Adequate bone marrow, liver and other organ functions and laboratory parameters;
Recovery from all AEs of previous anti-cancer therapies, including surgery and radiotherapy, to baseline or to CTCAE Grade ≤ 1, except for alopecia;Negative serum pregnancy (β hCG) test within 72 hrs before starting study treatment in all pre-menopausal women and women < 12 months after the onset of menopause.
* Exclusion Criteria:
- Progressive disease during or after prior combination treatment with PI3K-inhibitors and HSP90- inhibitors;
- history of prior significant toxicity from another PI3K- or HSP90- inhibitor requiring discontinuation of treatment;
- primary CNS tumor or uncontrolled CNS metastasest;
- Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment;
- Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L, history of clinically significant gestational diabetes mellitus or documented steroid-induced diabetes mellitus;Patients with diarrhea CTCAE Grade ≥ 2 ;
- Patients with acute or chronic pancreatitis; History or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO;
- Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BYL719;
- Patients receiving chronic slow-release formulation of Proton Pump Inhibitors (PPI), H2-antagonists or other gastric pH elevating agents;
- Treatment with therapeutic doses of coumarin-based anticoagulants (e.g., warfarin sodium, Coumadin®). Low doses of courmarin-based anticoagulants;
- Patients receiving chronic or high dose corticosteroids therapy; other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BYL719 + AUY922
Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination.
BYL719 tablets will be administered orally on a daily schedule (q.d.).
a b.i.d.
regimen may be explored.
AUY922 will be administered by IV infusion once per week.
|
AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence rate of Dose Limiting Toxicities.
Time Frame: cycle 1
|
To determine the maximum tolerated dose (MTD) and/or Recommended dose for expansion (RDE) and schedule of BYL719 and AUY922 when used as a combination in patients with advanced or metastatic gastric cancer carrying a molecular alteration of PIK3CA and/or an amplification of HER2. 1 cycle = 28days
|
cycle 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events (AEs)
Time Frame: duration of the study, an expected average of 24 months
|
To characterize the safety and tolerability of BYL719 and AUY922 in combination.
|
duration of the study, an expected average of 24 months
|
Best Overall Response (BOR) as per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
Time Frame: every 6 weeks
|
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination from Treatment start to disease progression
|
every 6 weeks
|
Plasma concentration versus time profiles of BYL719 as single agent an in combination with AUY922.
Time Frame: 2 months
|
To determine the single dose PK of BYL719 single dose, and multiple doses PK of BYL719.
|
2 months
|
Overall response rate (ORR) as per RECIST version 1.1
Time Frame: an expected average of 12 months
|
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
|
an expected average of 12 months
|
Progression free survival (PFS) as per RECIST version 1.1
Time Frame: every 6 weeks
|
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
|
every 6 weeks
|
Overall survival (OS)
Time Frame: approximately 1 year
|
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
|
approximately 1 year
|
Overall survival rate at 6 months (OS6)
Time Frame: 6 months
|
To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.
|
6 months
|
Frequency and severity of serious adverse events (SAEs)
Time Frame: duration of the study, an expected average of 24 months
|
To characterize the safety and tolerability of BYL719 and AUY922 in combination.
|
duration of the study, an expected average of 24 months
|
Plasma concentration versus time profile of AUY922 as single agent and in combination with BYL719
Time Frame: 2 months
|
To determine the single dose and multiple dose pharmacokinetics of AUY922
|
2 months
|
Plasma concentration versus time profile of the AUY922 metabolite BJP762
Time Frame: 2 months
|
To determine pharmacokinetics of BJP762 after single dose and multiple dose of AUY922
|
2 months
|
Severity of adverse events (AEs)
Time Frame: duration of the study, an expected average of 24 months
|
To characterize the safety and tolerability of BYL719 and AUY922 in combination.
|
duration of the study, an expected average of 24 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBYL719X2103
- 2011-005978-40 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
Royal Marsden NHS Foundation TrustRecruitingMetastatic Gastric Cancer | Metastatic Esophageal CancerUnited Kingdom
-
Triumvira Immunologics, Inc.Merck Sharp & Dohme LLCActive, not recruitingHER2 Positive Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerUnited States, Canada
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Karolinska University HospitalRecruitingBreast Cancer | Esophageal Neoplasms | HER2-positive Gastric Cancer | Gastric Neoplasms MalignantSweden
-
Shanghai Miracogen Inc.RecruitingLocally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerChina
-
Novartis PharmaceuticalsCompletedSquamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer | HER2 + Gastric CancerTaiwan, Spain, Canada, Korea, Republic of, United States
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingHER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction AdenocarcinomaAustria, Belgium, Germany, Italy
Clinical Trials on AUY922
-
Novartis PharmaceuticalsCompleted
-
M.D. Anderson Cancer CenterNovartisTerminated
-
National Taiwan University HospitalCompleted
-
Massachusetts General HospitalCompletedNon Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCNovartisCompletedGastrointestinal Stromal TumorUnited States
-
Dale Shepard, MD, PhDNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Novartis PharmaceuticalsCompletedBreast Cancer | Hematologic NeoplasmsNetherlands, Switzerland, United Kingdom, United States
-
Massachusetts General HospitalCompleted
-
University Health Network, TorontoNovartis PharmaceuticalsTerminatedAdenocarcinoma of the Pancreas | Metastatic DiseaseCanada
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsUnknownGastrointestinal Stromal TumorTaiwan